BBH VanEck Biotech ETF
Quote as of Oct 13, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 239.22 | Day Range | 235.25 – 239.96 |
| 52-Week Range | 172.92 – 246.55 | Volume | 6.14K |
| Avg Volume | 8.01K | AUM | $484.8M (Oct 13, 2026) |
| Expense Ratio | 0.35% | Yield (TTM) | 0.40% |
| NAV | 240.40 | Premium/Discount | -1.86% indicative |
| Inception | Dec 20, 2011 | Holdings | 25 |
| Issuer | VanEck | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 92189F726 | ISIN | US92189F7261 |
| Management | Not stated in source data | ||
About this ETF
The VanEck Biotech ETF (BBH) aims to closely reflect the price appreciation and income yield of the MVIS US Listed Biotech 25 Index (MVBBHTR), prior to the deduction of fees and expenses. This index monitors the aggregate performance of corporations involved in the research, manufacturing, promotion, and sale of medications derived from genetic insights and diagnostic technologies.
Description from the fund data provider · profile as of Oct 13, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +4.29% | +17.00% | +25.73% | +26.40% | +39.02% | +15.12% | +4.37% | +8.51% | +7.01% |
| Total return | +4.29% | +17.00% | +25.73% | +26.40% | +39.72% | +15.79% | +4.87% | +8.99% | +12.25% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 12, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.35% | Annual cost of a $10,000 investment | $35.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 10, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 27 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Amgen Inc | AMGN | 15.92% | 184.51K | $75.2M |
| 2 | Gilead Sciences Inc | GILD | 13.58% | 435.80K | $64.1M |
| 3 | Vertex Pharmaceuticals Inc | VRTX | 8.26% | 77.46K | $39.0M |
| 4 | Regeneron Pharmaceuticals Inc | REGN | 6.62% | 42.24K | $31.2M |
| 5 | Moderna Inc | MRNA | 6.47% | 155.16K | $30.6M |
| 6 | Natera Inc | NTRA | 5.27% | 63.70K | $24.9M |
| 7 | Iqvia Holdings Inc | IQV | 4.49% | 81.88K | $21.2M |
| 8 | Argenx Se | ARGX | 4.09% | 23.58K | $19.3M |
| 9 | Illumina Inc | ILMN | 4.08% | 72.82K | $19.3M |
| 10 | Revolution Medicines Inc | RVMD | 4.04% | 101.31K | $19.1M |
| 11 | Guardant Health Inc | GH | 2.91% | 83.07K | $13.8M |
| 12 | Biogen Inc | BIIB | 2.76% | 59.56K | $13.0M |
| 13 | Beone Medicines Ltd | ONC | 2.75% | 37.14K | $13.0M |
| 14 | Alnylam Pharmaceuticals Inc | ALNY | 2.56% | 53.94K | $12.1M |
| 15 | United Therapeutics Corp | UTHR | 2.30% | 20.38K | $10.9M |
| 16 | Incyte Corp | INCY | 2.16% | 90.46K | $10.2M |
| 17 | Insmed Inc | INSM | 1.94% | 91.17K | $9.2M |
| 18 | Charles River Laboratories Internationa | CRL | 1.58% | 25.09K | $7.5M |
| 19 | Biontech Se | BNTX | 1.55% | 79.56K | $7.3M |
| 20 | Neurocrine Biosciences Inc | NBIX | 1.44% | 48.29K | $6.8M |
| 21 | Icon Plc | ICLR | 1.26% | 36.10K | $5.9M |
| 22 | Bio-Techne Corp | TECH | 1.21% | 79.02K | $5.7M |
| 23 | Biomarin Pharmaceutical Inc | BMRN | 1.07% | 91.96K | $5.0M |
| 24 | Qiagen Nv | QGEN | 0.98% | 104.20K | $4.6M |
| 25 | Tempus Ai Inc | TEM | 0.98% | 66.91K | $4.6M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.40% | Paid (last 12 months) | $0.9565 |
| Frequency | Annual | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Dec 22, 2025 | Last payment | $0.9565 (Dec 26, 2025) |
| Growth 1Y | -23.58% | Growth 3Y / 5Y (ann.) | +8.49% / +9.48% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 22, 2025 | Dec 22, 2025 | Dec 26, 2025 | $0.9565 |
| Dec 23, 2024 | Dec 23, 2024 | Dec 24, 2024 | $1.2517 |
| Dec 18, 2023 | Dec 19, 2023 | Dec 22, 2023 | $0.7127 |
| Dec 19, 2022 | Dec 20, 2022 | Dec 23, 2022 | $0.7490 |
| Dec 20, 2021 | Dec 21, 2021 | Dec 27, 2021 | $0.3970 |
| Dec 21, 2020 | Dec 22, 2020 | Dec 28, 2020 | $0.6080 |
| Dec 23, 2019 | Dec 24, 2019 | Dec 30, 2019 | $0.4720 |
| Dec 20, 2018 | Dec 21, 2018 | Dec 27, 2018 | $0.5510 |
| Dec 18, 2017 | Dec 19, 2017 | Dec 22, 2017 | $0.6830 |
| Dec 19, 2016 | Dec 21, 2016 | Dec 23, 2016 | $0.3270 |
| Dec 21, 2015 | Dec 23, 2015 | Dec 28, 2015 | $0.3370 |
| Dec 23, 2013 | Dec 26, 2013 | Dec 30, 2013 | $0.0030 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 21.89% / 20.48% | Sharpe 1Y / 3Y | 1.79 / 0.699 |
| Max drawdown 1Y / 3Y | -10.55% / -22.74% | Sortino 1Y | 3.01 |
| Beta vs S&P 500 (3Y) | 0.695 | Correlation vs S&P 500 (1Y) | 0.367 |
| Downside deviation 1Y | 13.00% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 13, 2026. Formulas →
Liquidity
| Volume today | 6.14K | Average volume | 8.01K |
| AUM | $484.8M | Premium/Discount | -1.86% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $0.00 | 0.00% | $484.8M → $484.8M |
| 1 Month | $6.4M | +1.40% | $458.7M → $484.8M |
| 1 Week | $2.6M | +0.54% | $476.3M → $484.8M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for BBH
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.